Articles by bwarman

BCI and KCL collaboration develops a clinically-relevant CAR T cell imaging system

19th April 2018

A collaboration involving researchers from BCI’s Centre for Molecular Oncology, led by Dr Jane Sosabowski, and the ImmunoEngineering Group of King’s College London (KCL), led by Dr Sophie Papa, has developed an effective and clinically-relevant imaging system to monitor chimeric antigen receptor (CAR) T cells within the body. This system reduced the tumour burden in a pre-clinical model of prostate cancer and allowed for repeated and non-invasive assessment of CAR T cell localisation.

Read more

Follicular lymphoma marked by spatial tumour heterogeneity

23rd March 2018

A research team at the BCI, Queen Mary University of London, led by Dr Jessica Okosun, Centre for Haemato-Oncology, has found that tumours at different sites within the same patient with follicular lymphoma can be genetically diverse. This suggests that a sole biopsy is incapable of capturing all the genetic events in any given individual and presents a significant challenge when providing targeted therapies to treat this disease.

Read more

Dr Ranjit Manchanda awarded William Blair Bell Memorial Lecture

9th March 2018

Congratulations to our Dr Ranjit Manchanda, Centre for Experimental Cancer Medicine, who has been awarded the William Blair Bell Memorial Lecture prize. Dr Ranjit Manchanda was awarded with the prize on 8th February and presented his lecture, entitled ‘Population based germline testing and targeted ovarian cancer prevention,’ the following day.

Read more

Switching on survival signalling to drive drug resistance

27th February 2018

Researchers at the Barts Cancer Institute (BCI), Queen Mary University of London, led by Dr Richard Grose, Centre for Tumour Biology, have discovered that the loss of a single protein- PHLDA1- is sufficient for the development of drug resistance to a type of targeted therapy in endometrial and HER2-positive breast cancer cells.

Read more

The involvement of the microenvironment in tumour evolution

15th February 2018

For the first time, researchers at the Barts Cancer Institute (BCI), Queen Mary University of London, have profiled what happens at the site of tumour metastasis as cancer grows and develops. By looking closely at the tumour microenvironment (TME), the team led by Professor Fran Balkwill, Lead for the Centre for Cancer & Inflammation, has identified changes that occur as a type of ovarian cancer evolves.

Read more

Staying connected: New developments for tissue banking bioinformatics

1st February 2018

A team of researchers at the Barts Cancer Institute (BCI) of Queen Mary University of London have developed new analytical tools to aid in the analysis of tissue bank (TB) samples, which are an extremely valuable resource for scientists.

Read more

Search News
Categories
Archives
Tags